Joseph Galati, MD
Hepatology · Houston, TXNPI 1821069162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,231 of the $211,207 with a category attached, or 76.3%. 30 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 29.0% of the total. Among hepatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $284.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61K
- Intercept Pharmaceuticals, Inc.$61K
- Gilead$51K
- Madrigal Pharmaceuticals$25K
- Bausch Health US, LLC$9K
- AbbVie$1K
- plus $3K from 24 others
Across 57 payments — averaging $2462.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$95K
- Regeneron$19K
- Pfizer$13K
- Bausch Health US, LLC$7K
- Eli Lilly$2K
- Novartis$2K
- plus $1K from 3 others
What the payments were for
- Consulting fees$12,3136%
- Speaking & faculty fees$161,23176%
- Grants$3,1251%
- Travel & lodging$17,9949%
- Food & beverage$16,4958%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 221 | $61,176 |
| Intercept Pharmaceuticals, Inc. | 76 | $61,015 |
| Gilead | 213 | $50,889 |
| Madrigal Pharmaceuticals | 47 | $24,547 |
| Bausch Health US, LLC | 8 | $9,105 |
| AbbVie | 82 | $1,486 |
| Ipsen Biopharmaceuticals, Inc | 18 | $424 |
| Echosens North America, Inc. | 1 | $386 |
| Intra-sana Laboratories | 2 | $369 |
| Novo Nordisk | 16 | $280 |
| Perspectum Diagnostics Ltd | 6 | $233 |
| Fujifilm Healthcare Americas Corporation | 4 | $210 |
| Shionogi Inc | 11 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Ferring Pharmaceuticals Inc. | 6 | $129 |
| Mallinckrodt Hospital Products Inc. | 5 | $122 |
| Orphalan Inc | 4 | $115 |
| Albireo Pharma, Inc. | 1 | $103 |
| Ardelyx, Inc. | 2 | $37 |
| Olympus America Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $30 |
| AstraZeneca | 1 | $24 |
| Teleflex LLC | 1 | $23 |
| Merck | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Celltrion USA Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$58,399
- XIFAXAN$56,890
- Epclusa$41,455
- REZDIFFRA$17,323
- FibroScan$386
- Reltone 200 Mg$369
- Reltone 400 Mg$369
- Mavyret$114
- Bylvay$103
How this compares
$211,207 in reported general payments places this provider in the 90th percentile of 22 hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 331 | $1,134,606 |
| OcalivaObeticholic Acid | 15 | $201,028 |
| RezdiffraResmetirom | 22 | $97,404 |
| VemlidyTenofovir Alafenamide | 38 | $67,783 |
| Ursodiol | 247 | $43,161 |
| OzempicSemaglutide | 29 | $26,177 |
| LinzessLinaclotide | 13 | $12,045 |
| Lactulose | 251 | $10,161 |
| Tenofovir Disoproxil Fumarate | 62 | $6,004 |
| Entecavir | 33 | $5,496 |
| Spironolactone | 272 | $3,729 |
| Azathioprine | 65 | $3,513 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 22 | $3,092 |
| Pantoprazole Sodium | 226 | $2,699 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 42 | $2,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $61,176 | $1,137,698353 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $61,015 | $201,02815 claims |
| Madrigal PharmaceuticalsRezdiffra | $24,547 | $97,40422 claims |
| GileadVemlidy | $50,889 | $67,78338 claims |
| Novo NordiskOzempic | $280 | $26,17729 claims |
| AbbVieLinzess | $1,486 | $12,04513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 hepatology providers in Texas.
Other hepatology in Houston
- Norman SussmanHouston$45K
- Tuan PhamHouston$39K
- Maryam ZaferHouston$695
- Rise StriblingHouston$25
- Amit SingalDallas$534K
- Willis MaddreyDallas$289K
- Hesham ElgouhariDenison$147K
- Rashmee PatilMcAllen$146K
- William LeeDallas$101K
- Marlyn MayoDallas$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.